VCYT
VERACYTE, INC.
NASDAQ · Healthcare · Biotechnology · US
$43.80
+1.58%Year over year
Reported trailing growth
- Revenue
- +17.3%
- EBITDA
- +184.0%
- EBIT
- +592.2%
- EPS
- +314.4%
- Free cash flow
- +97.0%
- Operating cash flow
- +90.9%
Forward estimates
Based on analyst estimates
- Revenue
- +13.8%
- EBITDA
- +63.7%
- EPS
- +29.2%
Three-year CAGR
- Revenue
- +20.4%
- EBITDA
- +82.1%
- EBIT
- +359.4%
- Net income
- +174.9%
- EPS
- +162.5%
- Free cash flow
- +92.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026